Just Biotherapeutics and Teva Enter an Agreement for the Design and Development of a High Productivity Biomanufacturing Process
1 July 2019 - - US-based Just Biotherapeutics, Inc., an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, has entered into an agreement with Israeli generics company Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) (TASE: TEVA) for the design and development of a high productivity biomanufacturing process, the company said.
With the goal of significantly lowering the cost of manufacturing, Just will use its extensive knowledge and technological expertise on the design and development of a high yielding manufacturing process for one of Teva's more complex products in development.
Both companies firmly believe that innovation in both biologics development and manufacturing can play a role in increasing patient access.
The collaboration will be enabled by a cross-functional team based at Just's facility in Seattle, WA working together with Teva's Specialty R and D team based in West Chester, PA.


Related Headlines